Bibliography
- Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21
- Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59(4):364–73
- Larach MG, Brandom BW, Allen GC, et al. Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the united states. Anesthesiology 2008;108(4):603–11
- Brady JE, Sun LS, Rosenberg H, et al. Prevalence of malignant hyperthermia due to anesthesia in New york state, 2001-2005. Anesth Analg 2009;109(4):1162–6
- Klingler W, Heiderich S, Girard T, et al. Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis 2014;9:8
- Rosero EB, Adesanya AO, Timaran CH, et al. Trends and outcomes of malignant hyperthermia in the united states, 2000 to 2005. Anesthesiology 2009;110(1):89–94
- Gonsalves SG, Ng D, Johnston JJ, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology 2013;119(5):1043–53
- Wappler F. Malignant hyperthermia: current strategies for effective diagnosis and management. Expert Opin Orphan Drugs 2014;2:259–69
- Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the european malignant hyperthermia group. Br J Anaesth 2010;105(4):417–20
- Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56(4):254–62
- Schütte JK, Becker S, Burmester S, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs. Eur J Anaesthesiol 2011;28(4):256–64
- Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3(9):785–96
- Available from: http://www.ryanodex.com/wp-content/uploads/2014/07/ryanodex-prescribing-information.pdf
- Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=179703
- Drug approved to treat rare disorder associated with anesthesia. Available from: http://www.newswise.com/articles/view/621013/?sc=rsin
- What malignant hyperthermia association says about ryanodex. Available from: http://www.newswise.com/articles/view/622644/?sc=rsin
- Brandom BW, Larach MG, Chen MS, et al. Complications associated with the administration of dantrolene 1987 to 2006: A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the united states. Anesth Analg 2011;112(5):1115–23
- Grunau BE, Wiens MO, Brubacher JR. Dantrolene in the treatment of mdma-related hyperpyrexia: a systematic review. CJEM 2010;12(5):435–42
- Schütte JK, Schafer U, Becker S, et al. 3,4-methylenedioxymethamphetamine induces a hyperthermic and hypermetabolic crisis in pigs with and without a genetic disposition for malignant hyperthermia. Eur J Anaesthesiol 2013;30(1):29–37
- Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007;106(5):901–6